2011 was a year in which Harbin Pharmaceutical Group withstood unprecedented severe tests and strived to maintain steady economic development. The group closely focused on the set goals, fully implemented the "six major strategies", accelerated the integration of internal resources and the construction of key projects, and achieved a year-on-year sales revenue growth of 7.45% throughout the year, setting a new record high.
(1) Actively promote marketing innovation and achieve initial results in market expansion.
Harbin Pharmaceutical Group regards marketing management as the top priority of all its work, and has actively explored and boldly innovated in aspects such as structural adjustment, product sorting, and secondary development of old products. Through the implementation of marketing informatization projects and the dispatch of market supervisors, a rapid response mechanism closer to the market has been established, market supervision and assessment have been strengthened, and the management and control capabilities of key links such as channels, flows, and payment recovery have been further improved. Sanjing Pharmaceutical, Harbin Pharmaceutical No. 6 Factory, and Traditional Chinese Medicine Company have strengthened OTC team building, strengthened terminal market maintenance, integrated first-level agent and second-level distributor resources, continuously expanded terminal channels, focused on the sales of key incremental products, and achieved achieved better results. In 2011, the group produced 61 scale-advantaged varieties with sales revenue exceeding 10 million yuan, achieving a year-on-year sales revenue growth of 4.03%.
(2) Accelerate the pace of scientific and technological innovation and lay the foundation for comprehensive integration of scientific and technological resources.
In order to continuously promote the "integrated" operation of scientific and technological innovation, Harbin Pharmaceutical Group has established the Harbin Pharmaceutical Group Pharmaceutical Research Institute, which has identified a number of key R&D products in the fields of anti-tumor, cardiovascular, and biopharmaceuticals. , concentrated superior resources, intensified research efforts, and achieved phased results. Harbin Pharmaceutical General Factory’s new product cefmetazole sodium and its preparations won the first prize of Heilongjiang Province Science and Technology Progress Award. In 2011, the Group's first 17 new products, including the live vaccine for porcine PRRS, obtained production approval numbers. Among them, gemcitabine hydrochloride for injection, developed by the Pharmaceutical Research Institute and applied by Harbin Pharmaceutical Group Co., Ltd., is the first domestic batch of gemcitabine hydrochloride that fully meets the quality standards. Generic anti-tumor drugs approved by the United States Pharmacopeia (USP), which marks the Group’s new progress in the research and development of high-quality generic drugs. Four companies, Harbin Pharmaceutical Co., Ltd., Sanjing Pharmaceutical, Harbin Pharmaceutical Group Co., Ltd., and Harbin Pharmaceutical Group Co., Ltd., and Harbin Pharmaceutical Group Co., Ltd. successfully passed the high-tech enterprise certification review. Harbin Pharmaceutical Group Co., Ltd. successfully passed the on-site inspection of the new version of GMP certification, becoming the first certified enterprise in the province.
(3) Actively promote asset reorganization and management integration to improve the quality of corporate operations.
Harbin Pharmaceutical Group acquires all the shares of Harbin Pharmaceutical Group Co., Ltd. and Sanjing Pharmaceutical held by Harbin Pharmaceutical Group through a non-public issuance of shares to promote asset restructuring and integrate pharmaceutical platform resources. The restructuring plan has been reviewed and approved by the China Securities Regulatory Commission. This marks that Harbin Pharmaceutical Group has fully fulfilled its commitment to share reform, and has enabled the group company's pharmaceutical assets to be successfully listed as a whole. It has greatly improved Harbin Pharmaceutical Group's capital operation and industry integration capabilities, and laid a solid foundation for Harbin Pharmaceutical Group to implement strategic capital expansion in depth.
The "Eleventh Five-Year Plan" period was an extraordinary five years in the development history of Harbin Pharmaceutical Group. Faced with the impact of adverse factors such as the international financial crisis, the Group fully implemented the innovative development strategy, achieved fundamental adjustments to the property rights structure by introducing capital, turned development "bottlenecks" into competitive advantages, and made every effort to promote sound and rapid economic development of the Group, successfully completing For various tasks determined in the "Eleventh Five-Year Plan", "Harbin Yao people" used big ideas, great courage and generous efforts to draw a gratifying and proud economic growth curve, showing the brilliant achievements and greatness of the group's economic development. Progress:
From 2006 to 2010, the group’s main business income doubled in five years (average annual compound growth rate 15), profits and taxes increased 1.21 times in five years (average annual compound growth rate 17.2), and profits With an increase of 2.35 times in five years, the group's comprehensive economic strength has been significantly enhanced. This marks that with the joint efforts of all "Harbin Pharmaceuticals people", we have successfully achieved the planned development goal of "creating a new Harbin Pharmaceutical" during the "Eleventh Five-Year Plan" period and exceeded the "efficiency indicators" issued by the group's board of directors outperform the market” strategic mission.
Harbin Pharmaceutical Group's industry status has been significantly improved, and its scale and strength have ranked among the top 50 pharmaceutical companies in the world. It has been ranked among the top 100 pharmaceutical industry enterprises in China for five consecutive years, and has been among the top three non-prescription drug manufacturers in China for five consecutive years; Ranked among the top ten industrial enterprises in the province for five consecutive years, Harbin Pharmaceutical Group's economic scale has reached more than 70% of the total economic output of the province's pharmaceutical industry. Harbin Pharmaceutical Group has become one of the important economic supports that is indispensable for Harbin's economic and social development to achieve historic leaps and bounds.
By implementing large-scale project construction and promoting the development of emerging industries, the group's economic operation quality and industrial capabilities have reached a new level. The group has invested a total of 1.349 billion yuan and implemented 31 technical transformation projects. Up to now, 19 projects have been completed and put into production, with a total of 1.5 billion yuan in new sales revenue and 300 million yuan in new profits.
Through the implementation of technological innovation, the Group has obtained 60 new product approvals, and has another 55 varieties under research, of which 6 varieties under development are national first-class new drugs. A total of 89 nationally authorized patents have been obtained; 129 varieties have passed the national high-tech product certification. The number of the group's varieties with annual sales revenue exceeding 10 million yuan has reached 59, of which 22 varieties have sales exceeding 100 million yuan.
The influence and brand value of the "Harbin Pharmaceutical" brand have hit new highs repeatedly. The brand value of "Harbin Pharmaceuticals" has increased from 10.635 billion yuan in 2006 to 16.062 billion yuan. It has won the crown of the most valuable brand in China's pharmaceutical industry for five consecutive years, and was shortlisted for the "Top 500 Chinese Powerful Brands Influencing the World"; selected for the "Top 100 Asian Brands" The total estimated brand value of the four well-known Chinese trademarks, "Qiang", "Harbin Yao", "Sanjing", "Shiyitang" and "Gai Zhong Gai" has exceeded 30 billion yuan, creating huge intangible asset value. The group already owns 4 internationally registered trademarks, including "Harbin Pharmaceutical" and "Shiyitang", and ranks first in the national pharmaceutical industry in terms of number of advantageous brands. Harbin Pharmaceutical Group's total expenditure in supporting and participating in social welfare reached 250 million yuan, and it has won honorary titles such as the "Love Donation Award" from the Ministry of Civil Affairs and the "National Outstanding Enterprise in Harmonious Labor Relations". It has further established the image of Harbin Pharmaceutical Group as a large enterprise, a big brand, an honest and responsible corporate citizen in the society.
The year 2009 that has just passed has been the most severe test for Harbin Pharmaceutical Group since the new century. It was the year when medical reform policies and macroeconomic fluctuations caused the strongest impact and pressure on the company’s production and operations. The year in which the corporate management team and internal structure were deeply adjusted and the resources were integrated to the greatest extent. It was also the year in which tactics were transformed, progress was made through change, and the company's ability to withstand pressure and coldness was most rapidly enhanced.
Faced with the dual pressures of the financial crisis and pharmaceutical policy adjustments, we focused on "maintaining growth, adjusting structure, seizing projects, and promoting upgrades" to turn "crises" into "opportunities" and constantly optimize products and Industrial structure, we have tried every means to overcome the unfavorable factors of non-strategic capital expansion and slowdown in the growth rate of internal economic stock. We have written a brilliant chapter with courage and courage. The group economy has shown a good performance of total expansion, structural optimization, growth acceleration and quality improvement. situation, and all indicators hit record highs for the same period in history. According to incomplete statistics, in 2009, the group company's industrial added value increased by 12.16% year-on-year; operating income increased by 17.91% year-on-year; and profit increased by 15.05% year-on-year. Among them, the operating income growth rate was 6 percentage points higher than the average growth rate of the top 25 pharmaceutical listed companies in the country. The growth rate is 4 percentage points ahead. Since the establishment of Harbin Pharmaceutical Group in 1989, the group's comprehensive economic benefits have ranked first among pharmaceutical companies in Heilongjiang Province for 20 consecutive years; since 2005, profit indicators and brand value have ranked first among 4,738 pharmaceutical companies in the country for five consecutive years. In 2009, the estimated value of the "Harbin Pharmaceuticals" brand reached 15.19 billion yuan, an increase of 670 million yuan over the same period last year, ranking among the top 500 Asian brands.
Practice has proved that we must pay attention to strategic planning, tactical coordination, be broad-minded and quick-thinking, discover and cultivate favorable factors from adversity, and prepare for a rainy day at the beginning of a crisis; when a crisis strikes, take decisive action to ensure growth and expand domestic demand. In 2009, the Group's economy bucked the trend and achieved continuous success by combining structural adjustment and highlighting the three key words of integration, innovation and management in the "Harbin Pharmaceutical Ideas" to deal with the impact, and taking a scientific development path that adapts to the characteristics of Harbin Pharmaceutical Group. The key.
First, aim at one goal, integrate superior resources, and create a new pattern for the development of the group's industrial clusters. On the one hand, we insist on using a professional and intensive industrial development cooperation platform to actively absorb and strive for industrial transfers from multinational pharmaceutical companies, and promote the upgrading of the group's pillar industries with external increments. The Group has signed a letter of intent with a world-famous multinational pharmaceutical company to jointly operate high-end cephalosporin varieties, and plans to establish a long-term strategic partnership to jointly promote the accelerated development of China's antibiotic industry, marking the beginning of cooperation between Harbin Pharmaceutical Group and its international first-class counterparts. The Chinese Medicine Company has successfully increased its capital holding of Baichuan Pharmaceutical in Shangqiu, Henan Province, thereby realizing the company's sales network covering the Central Plains region. Baichuan Pharmaceutical's medicinal material base will also play a role in supplying the main production raw materials of the Chinese medicine company, further expanding the traditional Chinese medicine industry chain. On the other hand, we will re-examine the group's internal resource endowment from the perspective of sustainable development, implement a professional development strategy for production and operation, and gradually rationalize the division of labor and cooperation within the group's internal industrial chain based on the overall interests of the group, so as to become stronger and better in core areas. . The group's internal resource integration project has achieved phased results, achieving complementary advantages, maximum sharing of resources, intensive management and low-cost operations, and strengthening the main business industry chain of the health care products and direct sales sectors.
The second is to seize a main line, strengthen independent innovation, and form new highlights in subsequent varieties with scale advantages. In response to the market opportunities and demands brought about by the new medical reform policy, we will accelerate the reserve and research and development of competitive products with large market potential and high technical barriers, increase investment in scientific and technological research and development, and plan to introduce a number of important technologies with independent intellectual property rights to the public through public bidding. Products and standards cover 9 major fields and more than 60 categories. The scale and quantity are the largest in the history of the group. Under the strict requirements of the national SFDA for new drug registration, the group obtained 7 new drug production approvals throughout the year, and has 70 new products under development and 16 new products pending approval. Cefotiam Hydrochloride API and preparations of Harbin Pharmaceutical Group Corporation were awarded the "National Key New Product" certificate; Sanjing Pharmaceutical's "New Oral Sustained Release Preparation and Process Technology Platform Project" and Harbin Pharmaceutical Biological Company's "Innovative Anti-tumor Drug - Recombinant The "Endostatin 30 Peptide Development Project" was included in the "National Major New Drug Creation Project". With the powerful engine of the implementation of major science and technology projects of the Ministry of Science and Technology, the group's scientific and technological innovation system, new drug research and development, and new product pilot trials and industrialization will surely achieve greater development.
The third is to adhere to one principle, promote excellent management, and activate new power to increase speed and efficiency. Starting from mechanism innovation, we have continuously eliminated "management shortcomings" by strengthening internal control, and have made important progress in internal control construction, quality risk control, cost and expense control, production safety management, and management of senior leaders and cadres. In order to integrate the group's internal procurement channel resources, the group has established a bidding and procurement department to further standardize the bidding and procurement procedures for bulk materials and media advertising, step by step to promote the centralized management of the group's internal raw material procurement, and deeply implement the "Double Excellent Sunshine Procurement" project. The annual procurement cost saving was 451 million yuan. By strengthening the centralized management and control of cash flow, comprehensive budgeting and group finance, the role of the four "cash pools" of the Group Company, Harbin Pharmaceutical Co., Ltd., Sanjing Pharmaceutical and Pharmaceutical Company has been further brought into play, which has effectively improved the company's ability to control funds and the quality of its operations.
The turbulent year of 2009 has passed. In the "examination room" to face the financial crisis, Harbin Pharmaceutical Group was firm and calm, moving forward in the wind and rain, standing upright in the storm, overcoming serious difficulties and completing arduous tasks. Handed in an excellent answer sheet.